Merck (MSD outside of the US and Canada) has acquired Cidara Therapeutics, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, for approximately $9.2 billion. Cidara’s lead candidate, CD388, consists of a small molecule neuraminidase inhibitor stably conjugated to a proprietary Fc fragment of a human antibody designed… Read More
The Phase III study of CD388, a non-vaccine preventative of seasonal flu, has been accelerated by six months, biotechnology company Cidara Therapeutics has announced. The planned Phase III study will be a global, multicentre, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single… Read More
A novel, multi-specific CD73/PD-1 targeting drug-Fc conjugate (DFC) exhibited robust anti-tumour activity in humanised mouse models of colorectal cancer at low doses, according to data presented at the ESMO Immuno-Oncology (IO) Annual Congress. “We are thrilled to be presenting promising preclinical data on our novel multi-specific… Read More
